Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cingulate Inc. - Common Stock (NQ:CING)

10.47 +1.78 (+20.48%)
Streaming Delayed Price Updated: 11:39 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cingulate Inc. - Common Stock

News headline image
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate... 
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate... 
Via Newsfile
News headline image
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital... 
Via Newsfile
News headline image
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster Awards 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Present at 13th Annual LD Micro Invitational
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate, Indegene to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
From Indegene Inc
Via GlobeNewswire
Cingulate Inc. (NASDAQ: CING) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
News headline image
Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)
NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ:CING).... 
From Aegis Capital Corp.
Via AccessWire
Topics Retirement
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.